- Home
- LGHL vs PCSA Comparison
LGHL vs PCSA Comparison
Compare LGHL & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGHL
- PCSA
- Stock Information
- Founded
- LGHL 2015
- PCSA 2011
- Country
- LGHL Singapore
- PCSA United States
- Employees
- LGHL N/A
- PCSA N/A
- Industry
- LGHL Investment Bankers/Brokers/Service
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- LGHL Finance
- PCSA Health Care
- Exchange
- LGHL Nasdaq
- PCSA Nasdaq
- Market Cap
- LGHL 1.4M
- PCSA 1.2M
- IPO Year
- LGHL N/A
- PCSA N/A
- Fundamental
- Price
- LGHL $2.96
- PCSA $0.24
- Analyst Decision
- LGHL
- PCSA Strong Buy
- Analyst Count
- LGHL 0
- PCSA 1
- Target Price
- LGHL N/A
- PCSA $6.00
- AVG Volume (30 Days)
- LGHL 242.2K
- PCSA 6.0M
- Earning Date
- LGHL 05-06-2025
- PCSA 05-09-2025
- Dividend Yield
- LGHL N/A
- PCSA N/A
- EPS Growth
- LGHL N/A
- PCSA N/A
- EPS
- LGHL N/A
- PCSA N/A
- Revenue
- LGHL $13,659,110.00
- PCSA N/A
- Revenue This Year
- LGHL N/A
- PCSA N/A
- Revenue Next Year
- LGHL N/A
- PCSA N/A
- P/E Ratio
- LGHL N/A
- PCSA N/A
- Revenue Growth
- LGHL 11.24
- PCSA N/A
- 52 Week Low
- LGHL $2.59
- PCSA $0.22
- 52 Week High
- LGHL $30.90
- PCSA $3.10
- Technical
- Relative Strength Index (RSI)
- LGHL 37.30
- PCSA 32.80
- Support Level
- LGHL $2.76
- PCSA $0.20
- Resistance Level
- LGHL $3.56
- PCSA $0.25
- Average True Range (ATR)
- LGHL 0.44
- PCSA 0.06
- MACD
- LGHL 0.10
- PCSA 0.01
- Stochastic Oscillator
- LGHL 31.90
- PCSA 33.54
About LGHL Lion Group Holding Ltd.
Lion Group Holding Ltd is an investor-focused trading platform that offers various products and services. The company's current business lines include total return swap (TRS) trading business, contracts for difference (CFD) trading services, Hong Kong-based Over-The-Counter (OTC) stock options trading business, and futures and securities brokerage services. It provides these services through its Lion Brokers Pro and a variety of other applications. The company generates a majority of its revenue from its CFD trading services business. Geographically, the firm's key revenue-generating market is Hong Kong.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).